Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tachykinins: receptor to effector

A M Khawaja1, D F Rogers

  • 1National Heart and Lung Institute (Imperial College), London, U.K.

The International Journal of Biochemistry & Cell Biology
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of airway mucin gene expression.

Methods in molecular medicine·2011
Same author

Intravenously administered oligonucleotides can be delivered to conducting airway epithelium via the bronchial circulation.

Gene therapy·2006
Same author

Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.

Neurotoxicity research·2006
Same author

Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma.

Respiratory medicine·2005
Same author

Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD.

Thorax·2003
Same author

Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease.

Expert opinion on pharmacotherapy·2001

Tachykinins, including substance P, are peptide neurotransmitters that bind to NK1, NK2, and NK3 receptors. Selective ligands reveal diverse roles and therapeutic potential for conditions like pain and neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Tachykinins are conserved peptide neurotransmitters.
  • Mammalian tachykinins include substance P, neurokinin A, and neurokinin B.
  • These bind to three specific receptor types: NK1, NK2, and NK3.

Purpose of the Study:

  • To explore the roles of tachykinins and their receptors.
  • To investigate the therapeutic potential of selective tachykinin receptor ligands.

Main Methods:

  • Cloning of tachykinin receptors, revealing their G-protein-linked nature.
  • Development and use of selective agonists and antagonists.
  • Analysis of receptor binding potencies and signaling pathways.

Main Results:

Related Experiment Videos

  • Tachykinin receptors are G-protein-linked receptors with seven transmembrane segments.
  • Selective ligands highlight inter- and intraspecies differences in binding.
  • Tachykinin-receptor interaction activates Gq, leading to calcium release and cellular response.

Conclusions:

  • Tachykinins mediate diverse physiological effects in the central nervous system and periphery.
  • Selective non-peptide antagonists offer therapeutic potential for chronic pain, neurodegenerative diseases, and inflammatory conditions.